Regeneron reports COVID-19 antibody cocktail reduced infection risk by 82% for 8 months — so far
Biotech giant Regeneron has claimed that its antibody cocktail reduces the risk of infectious-disease infection by nearly 82% for eight months. The company on Monday announced the results of its clinical trials run in partnership with the National Institute of Allergy and Infectious Diseases. iStock “During the 8-month assessment period, there were 0 hospitalizations for…